Method for differentiation of pluripotent stem cells into multi-competent renal precursors

US10138468B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10138468-B2
Application numberUS-201615010389-A
CountryUS
Kind codeB2
Filing dateJan 29, 2016
Priority dateJul 29, 2013
Publication dateNov 27, 2018
Grant dateNov 27, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of: a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium, b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), and c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1. 2. The method of claim 1 , wherein the pluripotency medium of step a) is a serum-free medium supplemented with an inhibitor of the Rho-associated coiled-coil forming protein serine/threonine kinase family of protein kinases (ROCK kinase inhibitor). 3. The method of claim 2 , wherein the ROCK kinase inhibitor is selected from the group consisting of 1-(5-Isoquinolinesulfonyl) homopiperazine, N-Benzyl-2-(pyrimidin-4-ylamino) thiazole-4-carboxamide, and (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride). 4. The method of claim 1 , wherein the medium of step b) is a serum free medium supplemented with insulin, transferrin and progesterone. 5. The method of claim 1 , wherein step a) comprises incubating the cells in the pluripotency medium for 18 hours to 30 hours. 6. The method of claim 1 , wherein step b) comprises incubating the cells in the medium for 3 to 4 days. 7. The method of claim 1 , wherein step c) comprises incubating the cells in the medium for 18 hours to 48 hours. 8. The method of claim 1 , wherein the pluripotent stem cell is an induced pluripotent stem cell. 9. The method claim 8 , wherein the induced pluripotent stem cell is obtained from a subject suffering from a renal disease. 10. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of: a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium, b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indo-1-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1, and d) incubating the renal precursor cells of step c) in a medium comprising retinoic acid and vitamin D3 to obtain proliferating podocytes. 11. The method of claim 10 , wherein the medium of step d) is supplemented with 10-200 nM vitamin D3.

Assignees

Inventors

Classifications

  • Kinases (EC 2.7.) · CPC title

  • from artificially induced pluripotent stem cells · CPC title

  • Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title

  • of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title

  • Insulin-transferrin; Insulin-transferrin-selenium · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10138468B2 cover?
This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iP…
Who is the assignee on this patent?
Hoffmann La Roche
What technology area does this patent fall under?
Primary CPC classification C12N5/0687. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).